Business
Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
CINCINNATI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced an update to its presentation at the H.C. Wainwright 24th Annual Global Investment Conference. Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines, will present a company overview in person, with an option to view the presentation online via webcast link, on Monday, September 12, 2022 at 9am EDT. Session details are as follows: Date:Monday, September 12, 2022 @ Lotte New York Palace Hotel, New York, NYTime:9am Eastern Daylight Time (EDT)Title:Blue Water Vaccines Company PresentationBWV Participant:Joseph Hernandez, Chairman and Chief Executive OfficerRegistration Link:https://hcwevents.com/annualconference/Webcast Link:https://journey.ct.events/view/1ccd7c1d-edad-4ecc-b9b3-dee991919a61 BWV’s management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at [email protected] or contact BWV at (513) 620-4101. About Blue Water Vaccines Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com. Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Ac...